{"id":"https://openalex.org/W4376613722","doi":"https://doi.org/10.1016/j.esmoop.2023.101412","title":"223P Real-world effectiveness of palbociclib (Pal) plus an aromatase inhibitor (AI) vs AI alone in patients who have metastatic breast cancer (mBC) with lung or liver metastases","display_name":"223P Real-world effectiveness of palbociclib (Pal) plus an aromatase inhibitor (AI) vs AI alone in patients who have metastatic breast cancer (mBC) with lung or liver metastases","publication_year":2023,"publication_date":"2023-05-01","ids":{"openalex":"https://openalex.org/W4376613722","doi":"https://doi.org/10.1016/j.esmoop.2023.101412"},"language":"en","primary_location":{"id":"doi:10.1016/j.esmoop.2023.101412","doi":"https://doi.org/10.1016/j.esmoop.2023.101412","is_oa":true,"landing_page_url":"https://doi.org/10.1016/j.esmoop.2023.101412","pdf_url":"http://www.esmoopen.com/article/S2059702923006385/pdf","source":{"id":"https://openalex.org/S4210217024","display_name":"ESMO Open","issn_l":"2059-7029","issn":["2059-7029"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-b","doyens","jufo-2","ki-jl-1","medline","norway-1","poland-40","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":"cc-by-nc-nd","license_id":"https://openalex.org/licenses/cc-by-nc-nd","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"ESMO Open","raw_type":"journal-article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["crossref","doaj"],"open_access":{"is_oa":true,"oa_status":"gold","oa_url":"http://www.esmoopen.com/article/S2059702923006385/pdf","any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5044108002","display_name":"Adam Brufsky","orcid":"https://orcid.org/0000-0001-8080-7960","observed_orcids":["https://orcid.org/0000-0001-8080-7960","https://orcid.org/0009-0006-2725-3579"]},"institutions":[{"id":"https://openalex.org/I4210128526","display_name":"UPMC Hillman Cancer Center","ror":"https://ror.org/03bw34a45","country_code":"US","type":"facility","lineage":["https://openalex.org/I170201317","https://openalex.org/I4210128526"]},{"id":"https://openalex.org/I4210134769","display_name":"University of Pittsburgh Medical Center","ror":"https://ror.org/04ehecz88","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210098814","https://openalex.org/I4210134769"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"A. Brufsky","raw_affiliation_strings":["Division of Hematology/Oncology, UPMC Hillman Cancer Center, Department of Medicine/University of Pittsburgh Medical Center, Pittsburgh, PA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Division of Hematology/Oncology, UPMC Hillman Cancer Center, Department of Medicine/University of Pittsburgh Medical Center, Pittsburgh, PA, USA","institution_ids":["https://openalex.org/I4210128526","https://openalex.org/I4210134769"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5090463130","display_name":"Xianchen Liu","orcid":"https://orcid.org/0000-0003-0411-1050","observed_orcids":["https://orcid.org/0000-0003-0411-1050","https://orcid.org/0000-0002-4325-2545"]},"institutions":[{"id":"https://openalex.org/I180857899","display_name":"Pfizer (United States)","ror":"https://ror.org/01xdqrp08","country_code":"US","type":"company","lineage":["https://openalex.org/I180857899"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"X. Liu","raw_affiliation_strings":["Medical, Pfizer Inc., New York, NY, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Medical, Pfizer Inc., New York, NY, USA","institution_ids":["https://openalex.org/I180857899"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5064628466","display_name":"B. Li","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I180857899","display_name":"Pfizer (United States)","ror":"https://ror.org/01xdqrp08","country_code":"US","type":"company","lineage":["https://openalex.org/I180857899"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"B. Li","raw_affiliation_strings":["Medical, Pfizer Inc., New York, NY, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Medical, Pfizer Inc., New York, NY, USA","institution_ids":["https://openalex.org/I180857899"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5042491180","display_name":"Lynn McRoy","orcid":"https://orcid.org/0000-0002-0986-5364","observed_orcids":["https://orcid.org/0000-0002-0986-5364"]},"institutions":[{"id":"https://openalex.org/I180857899","display_name":"Pfizer (United States)","ror":"https://ror.org/01xdqrp08","country_code":"US","type":"company","lineage":["https://openalex.org/I180857899"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"L. McRoy","raw_affiliation_strings":["Medical, Pfizer Inc., New York, NY, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Medical, Pfizer Inc., New York, NY, USA","institution_ids":["https://openalex.org/I180857899"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5057738743","display_name":"C. Chen","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I180857899","display_name":"Pfizer (United States)","ror":"https://ror.org/01xdqrp08","country_code":"US","type":"company","lineage":["https://openalex.org/I180857899"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"C. Chen","raw_affiliation_strings":["Medical, Pfizer Inc., New York, NY, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Medical, Pfizer Inc., New York, NY, USA","institution_ids":["https://openalex.org/I180857899"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5064168158","display_name":"Rachel M. Layman","orcid":"https://orcid.org/0000-0002-8663-0331","observed_orcids":["https://orcid.org/0000-0002-8663-0331"]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"R.M. Layman","raw_affiliation_strings":["Breast Medical Oncology - Unit 1354, The University of Texas MD Anderson Cancer Center, Houston, TX, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Breast Medical Oncology - Unit 1354, The University of Texas MD Anderson Cancer Center, Houston, TX, USA","institution_ids":["https://openalex.org/I1343551460"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5090188675","display_name":"Hope S. Rugo","orcid":"https://orcid.org/0000-0001-6710-4814","observed_orcids":["https://orcid.org/0000-0001-6710-4814"]},"institutions":[{"id":"https://openalex.org/I180670191","display_name":"University of California, San Francisco","ror":"https://ror.org/043mz5j54","country_code":"US","type":"education","lineage":["https://openalex.org/I180670191"]},{"id":"https://openalex.org/I4210167126","display_name":"UCSF Helen Diller Family Comprehensive Cancer Center","ror":"https://ror.org/05yndxy10","country_code":"US","type":"facility","lineage":["https://openalex.org/I180670191","https://openalex.org/I4210110664","https://openalex.org/I4210167126"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"H.S. Rugo","raw_affiliation_strings":["Breast Department, University of California San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Breast Department, University of California San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, USA","institution_ids":["https://openalex.org/I180670191","https://openalex.org/I4210167126"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":6,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":{"value":3290,"currency":"USD","value_usd":3290},"apc_paid":{"value":3290,"currency":"USD","value_usd":3290},"fwci":0.2601,"has_fulltext":true,"cited_by_count":2,"citation_normalized_percentile":{"value":0.5073799,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":94,"max":96},"biblio":{"volume":"8","issue":"1","first_page":"101412","last_page":"101412"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T12829","display_name":"Advanced Breast Cancer Therapies","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T12829","display_name":"Advanced Breast Cancer Therapies","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10183","display_name":"Breast Cancer Treatment Studies","score":0.0,"subfield":{"id":"https://openalex.org/subfields/1306","display_name":"Cancer Research"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T11914","display_name":"PARP inhibition in cancer therapy","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/palbociclib","display_name":"palbociclib","score":1.0},{"id":"https://openalex.org/keywords/aromatase-inhibitors","display_name":"aromatase inhibitors","score":0.8870000243186951},{"id":"https://openalex.org/keywords/metastatic-breast-cancer","display_name":"metastatic breast cancer","score":0.8600000143051147},{"id":"https://openalex.org/keywords/cdk4-6-inhibitors","display_name":"CDK4/6 inhibitors","score":0.8500000238418579},{"id":"https://openalex.org/keywords/hr-her2-breast-cancer","display_name":"hormone receptor-positive HER2-negative breast cancer","score":0.8190000057220459},{"id":"https://openalex.org/keywords/lung-metastasis","display_name":"lung metastasis","score":0.921999990940094},{"id":"https://openalex.org/keywords/liver-metastases","display_name":"liver metastasis","score":1.0},{"id":"https://openalex.org/keywords/visceral-metastasis","display_name":"visceral metastases","score":0.9629999995231628},{"id":"https://openalex.org/keywords/first-line-treatment","display_name":"first-line therapy","score":0.7099999785423279},{"id":"https://openalex.org/keywords/overall-survival","display_name":"overall survival","score":0.8109999895095825},{"id":"https://openalex.org/keywords/progression-free-survival","display_name":"progression-free survival","score":0.9559999704360962},{"id":"https://openalex.org/keywords/real-world-effectiveness","display_name":"real-world effectiveness","score":0.800000011920929},{"id":"https://openalex.org/keywords/endocrine-therapy","display_name":"endocrine therapy","score":0.8399999737739563}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.8032206892967224},{"id":"https://openalex.org/C2775930923","wikidata":"https://www.wikidata.org/wiki/Q12859063","display_name":"Metastatic breast cancer","level":4,"score":0.608420729637146},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.6011518836021423},{"id":"https://openalex.org/C2779013556","wikidata":"https://www.wikidata.org/wiki/Q181876","display_name":"Metastasis","level":3,"score":0.5370174646377563},{"id":"https://openalex.org/C207103383","wikidata":"https://www.wikidata.org/wiki/Q3930246","display_name":"Hazard ratio","level":3,"score":0.5297335982322693},{"id":"https://openalex.org/C2779744173","wikidata":"https://www.wikidata.org/wiki/Q15269707","display_name":"Palbociclib","level":5,"score":0.48095670342445374},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.4765744209289551},{"id":"https://openalex.org/C72563966","wikidata":"https://www.wikidata.org/wiki/Q1303415","display_name":"Cohort","level":2,"score":0.4374282658100128},{"id":"https://openalex.org/C90924648","wikidata":"https://www.wikidata.org/wiki/Q120569","display_name":"Gastroenterology","level":1,"score":0.43250900506973267},{"id":"https://openalex.org/C530470458","wikidata":"https://www.wikidata.org/wiki/Q128581","display_name":"Breast cancer","level":3,"score":0.42202165722846985},{"id":"https://openalex.org/C2777714996","wikidata":"https://www.wikidata.org/wiki/Q7886","display_name":"Lung","level":2,"score":0.4207285940647125},{"id":"https://openalex.org/C167135981","wikidata":"https://www.wikidata.org/wiki/Q2146302","display_name":"Retrospective cohort study","level":2,"score":0.41766855120658875},{"id":"https://openalex.org/C2780739268","wikidata":"https://www.wikidata.org/wiki/Q2112244","display_name":"Progression-free survival","level":3,"score":0.4166828393936157},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.3784375786781311},{"id":"https://openalex.org/C3019894029","wikidata":"https://www.wikidata.org/wiki/Q332823","display_name":"Overall survival","level":2,"score":0.13279733061790466},{"id":"https://openalex.org/C44249647","wikidata":"https://www.wikidata.org/wiki/Q208498","display_name":"Confidence interval","level":2,"score":0.0}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1016/j.esmoop.2023.101412","doi":"https://doi.org/10.1016/j.esmoop.2023.101412","is_oa":true,"landing_page_url":"https://doi.org/10.1016/j.esmoop.2023.101412","pdf_url":"http://www.esmoopen.com/article/S2059702923006385/pdf","source":{"id":"https://openalex.org/S4210217024","display_name":"ESMO Open","issn_l":"2059-7029","issn":["2059-7029"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-b","doyens","jufo-2","ki-jl-1","medline","norway-1","poland-40","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":"cc-by-nc-nd","license_id":"https://openalex.org/licenses/cc-by-nc-nd","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"ESMO Open","raw_type":"journal-article"}],"best_oa_location":{"id":"doi:10.1016/j.esmoop.2023.101412","doi":"https://doi.org/10.1016/j.esmoop.2023.101412","is_oa":true,"landing_page_url":"https://doi.org/10.1016/j.esmoop.2023.101412","pdf_url":"http://www.esmoopen.com/article/S2059702923006385/pdf","source":{"id":"https://openalex.org/S4210217024","display_name":"ESMO Open","issn_l":"2059-7029","issn":["2059-7029"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-b","doyens","jufo-2","ki-jl-1","medline","norway-1","poland-40","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":"cc-by-nc-nd","license_id":"https://openalex.org/licenses/cc-by-nc-nd","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"ESMO Open","raw_type":"journal-article"},"sustainable_development_goals":[{"score":0.9940000176429749,"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3"}],"study_designs":[{"display_name":"Observational Study","id":"https://openalex.org/study-designs/observational-study"}],"awards":[],"funders":[{"id":"https://openalex.org/F4320307765","display_name":"Pfizer","ror":"https://ror.org/01xdqrp08"},{"id":"https://openalex.org/F4320307770","display_name":"AstraZeneca","ror":"https://ror.org/04r9x1a08"}],"has_content":{"grobid_xml":true,"pdf":true},"content_urls":{"pdf":"https://content.openalex.org/works/W4376613722.pdf","grobid_xml":"https://content.openalex.org/works/W4376613722.grobid-xml"},"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W4388296749","https://openalex.org/W4220674723","https://openalex.org/W4283796995","https://openalex.org/W4304190250","https://openalex.org/W2977725664","https://openalex.org/W7131290469","https://openalex.org/W2947775600","https://openalex.org/W4413111934","https://openalex.org/W4406074219","https://openalex.org/W4411287111"],"abstract_inverted_index":{"Cyclin-dependent":[0],"kinase":[1],"4/6":[2],"inhibitors":[3],"(CDK4/6is)":[4],"combined":[5],"with":[6,16,42,66,75,96,161,167,174,181,189,199,206,262,265],"endocrine":[7],"therapy":[8],"are":[9,45],"the":[10,55,218,253],"standard":[11],"of":[12,31,101,255],"care":[13],"for":[14,40,143,260],"patients":[15,41,156,188,205,261],"hormone":[17],"receptor-positive":[18],"(HR+)/human":[19],"epidermal":[20],"growth":[21],"factor":[22],"receptor":[23],"2-negative":[24],"(HER2\u2212)":[25],"mBC.":[26],"However,":[27],"real-world":[28,148],"comparative":[29],"effectiveness":[30],"CDK4/6is":[32],"plus":[33,79],"an":[34,37,80,83,241],"AI":[35,38,81,84,178,221,224,239,242,259],"versus":[36,223,240],"alone":[39,85,225,243],"visceral":[43,266],"metastases":[44,73,193],"limited.":[46],"This":[47,152],"retrospective":[48],"study":[49,61,153],"used":[50,134],"electronic":[51],"health":[52],"records":[53],"from":[54],"US":[56],"Flatiron":[57],"Health":[58],"database.":[59],"The":[60,127],"included":[62,154],"women":[63],"and":[64,69,118,140,147,170,184,191,212,233,247],"men":[65],"HR+/HER2\u2212":[67,263],"mBC":[68,187,264],"lung":[70,162,190,207],"or":[71,82,208],"liver":[72,168,192,209],"treated":[74],"first-line":[76],"(1L)":[77],"Pal":[78,176,219,237,257],"between":[86,108],"February":[87],"2015":[88],"to":[89,135],"March":[90],"2020":[91],"in":[92,186,217,249],"routine":[93,250],"clinical":[94],"practice":[95],"a":[97,124],"data":[98],"cutoff":[99],"date":[100],"September":[102],"2020.":[103],"Patient":[104],"characteristics":[105],"were":[106,197,214],"balanced":[107],"each":[109],"treatment":[110,115],"cohort":[111],"by":[112],"stabilized":[113],"inverse-probability":[114],"weighting":[116],"(sIPTW)":[117],"propensity":[119],"score":[120],"matching":[121],"(PSM)":[122],"as":[123],"sensitivity":[125],"analysis.":[126],"weighted":[128],"Cox":[129],"proportional":[130],"hazards":[131],"model":[132],"was":[133,179],"compute":[136],"hazard":[137],"ratios":[138],"(HR)":[139],"95%":[141],"CIs":[142],"overall":[144],"survival":[145,150],"(OS)":[146],"progression-free":[149],"(rwPFS).":[151],"891":[155,204],"total":[157],"(n":[158],"=":[159,165,172,230],"622":[160],"metastasis,":[163,169],"n":[164,171],"376":[166],"107":[173],"both).":[175],"+":[177,220,238,258],"associated":[180],"prolonged":[182,216,245],"OS":[183,211,246],"rwPFS":[185,213,248],"(Table);":[194],"PSM":[195],"results":[196],"consistent":[198],"these":[200],"findings.":[201],"For":[202],"all":[203],"metastases,":[210],"significantly":[215],"group":[222,226],"following":[227],"sIPTW":[228],"(HR":[229],"0.64;":[231],"P<0.001":[232],"0.57;":[234],"P<0.001,":[235],"respectively).":[236],"demonstrated":[244],"practice,":[251],"supporting":[252],"use":[254],"1L":[256],"metastatic":[267],"diseases.":[268]},"counts_by_year":[{"year":2025,"cited_by_count":2}],"updated_date":"2026-10-16T09:59:22.235173","created_date":"2023-05-17T00:00:00"}